KANCHAN M MAHON

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry ENDWELL, NY NPI 1326163239

General Payments — all program years on this page

$4,245.16

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 257
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $571.32 across 19 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $571.3219

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2018 $847.1553
2019 $854.1370
2020 $477.4033
2021 $240.4015
2022 $365.6621
2023 $889.1046
2024 $571.3219

Records — PY2024 (19)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1101432339 E.R. Squibb & Sons, L.L.C. $24.11 11/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101432353 E.R. Squibb & Sons, L.L.C. $124.42 11/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104930356 ABBVIE INC. $21.08 05/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137627608 Takeda Pharmaceuticals U.S.A., Inc. $23.55 02/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137627610 Takeda Pharmaceuticals U.S.A., Inc. $20.93 04/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137627612 Takeda Pharmaceuticals U.S.A., Inc. $22.71 05/31/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137627614 Takeda Pharmaceuticals U.S.A., Inc. $22.50 07/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137627616 Takeda Pharmaceuticals U.S.A., Inc. $35.00 07/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143268959 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $23.44 08/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143268962 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $20.97 08/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1145941640 Lundbeck LLC $27.11 04/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1145941642 Lundbeck LLC $29.68 07/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1145941644 Lundbeck LLC $33.14 10/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148295046 Axsome Therapeutics, Inc. $17.84 01/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148295048 Axsome Therapeutics, Inc. $20.39 03/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151758402 Teva Pharmaceuticals USA, Inc. $26.71 03/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151758461 Teva Pharmaceuticals USA, Inc. $18.29 06/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151758497 Teva Pharmaceuticals USA, Inc. $26.71 08/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151758554 Teva Pharmaceuticals USA, Inc. $32.74 11/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.